10-Q: Aclarion Inc. Reports Increased Revenue and Completes Multiple Offerings in Q1 2025

Aclarion Inc.'s Q1 2025 shows revenue growth driven by increased patient scans, alongside significant financing activities including public and direct offerings.

Summary

• Aclarion Inc. reported financial results for the quarter ended March 31, 2025.
• Revenue increased by 88% to $18,991 compared to $10,114 in the same period last year, driven by increased patient-pay scans at Radnet facilities.
• The company incurred a net loss of $2,037,436, compared to a net loss of $2,399,102 in the prior year.
• Operating expenses totaled $1,487,437, up from $1,265,945 in the prior year, primarily due to increased sales and marketing expenses related to the CLARITY trial.
• The company completed several financing activities, including registered direct offerings and an underwritten public offering, raising a total of $20.1 million in gross proceeds.
• As of March 31, 2025, Aclarion had cash and cash equivalents of $14,760,272.
• The company believes its current cash will fund operating expenses and capital expenditure requirements into the third quarter of 2026.

Sentiment

Score: 6

Explanation: The sentiment is neutral. While revenue increased significantly and the company secured substantial funding, it continues to operate at a loss and faces challenges with internal controls. The outlook is cautiously optimistic, dependent on continued growth and effective financial management.

Positives

• Revenue increased by 88% year-over-year, indicating growing market adoption of Nociscan reports.
• Successful capital raising activities have significantly strengthened the company's cash position.
• The redemption of Series B Preferred Stock simplifies the capital structure.
• The exercise of Series C warrants provides additional capital to the company.
• Research and development expenses decreased by 17% due to reduced regulatory and quality system work and contractor support.

Negatives

• The company continues to operate at a net loss, with a loss of $2,037,436 for the quarter.
• Operating expenses increased by 17%, driven by sales and marketing expenses.
• The company paid $687,500 to settle a dispute under the 'fee tail' provision of an investment banking agreement.
• The company's disclosure controls and procedures are not effective in providing material information required to be included in our periodic SEC filings on a timely basis.

Risks

• The company's ability to continue as a going concern is dependent on raising additional capital.
• The company's disclosure controls and procedures are not effective in providing material information required to be included in our periodic SEC filings on a timely basis.
• The company's internal control over financial reporting was not effective as of December 31, 2024 due to material weaknesses related to (1) a limited segregation of duties due to our lack of formal control documentation, limited resources, and the small number of employees, and (2) a lack of adequate accounting resources to properly account for complex accounting transactions.
• The company may need to obtain substantial additional funds to achieve its business objectives, and adequate additional funds may not be available to us on acceptable terms, or at all.

Future Outlook

The company believes its current cash will fund its operating expenses and capital expenditure requirements into the third quarter of 2026. The Company will need to raise additional funds to continue funding our technology development and commercialization efforts.

Industry Context

The company operates in the healthcare technology sector, leveraging magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments. The increased revenue suggests a growing demand for their Nociscan reports, potentially driven by increased awareness and adoption within the medical community. The company's ability to secure additional funding is crucial for continued growth and development in this competitive landscape.

Comparison to Industry Standards

• It is difficult to compare Aclarion's results directly to industry standards due to its unique technology and focus within the healthcare sector.
• However, the 88% revenue growth indicates a strong performance compared to some other early-stage medical technology companies.
• Companies like Exact Sciences (EXAS) and Guardant Health (GH) have demonstrated the potential for significant growth in the diagnostics space, but they operate on a larger scale and with different technologies.
• Aclarion's success will depend on its ability to continue driving adoption of its Nociscan reports and securing necessary funding for expansion.

Legal Proceedings

• In March 2025 we paid $687,500 to settle a dispute under the 'fee tail' provision of an investment banking agreement that the Company had previously entered into.

Stakeholder Impact

• Shareholders: Dilution from recent equity offerings, but potential for long-term value creation if the company can achieve profitability.
• Employees: Continued employment and potential for growth within the company.
• Customers: Access to innovative diagnostic technology.
• Suppliers: Continued business relationships.
• Creditors: Repayment of debt obligations.

Next Steps

• Continue the CLARITY trial and site evaluations.
• Manage cash position and secure long-term funding.
• Drive adoption of Nociscan reports.
• Enhance internal control over financial reporting.

Key Dates

Keywords

Aclarion, Nociscan, Revenue, Net Loss, Capital Raise, Public Offering, Registered Direct Offering, Warrants, Preferred Stock, Financial Results, CLARITY Trial